Holen Sie sich die Stockscreener-App
86.61
1.02%
-0.796
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$87.41
Offen:
$86.83
24-Stunden-Volumen:
6.87M
Relative Volume:
0.58
Marktkapitalisierung:
$150.96B
Einnahmen:
$45.13B
Nettoeinkommen (Verlust:
$6.28B
KGV:
24.13
EPS:
3.5895
Netto-Cashflow:
$7.38B
1W Leistung:
-2.59%
1M Leistung:
-5.06%
6M Leistung:
-32.69%
1J Leistung:
-34.11%
1-Tages-Spanne:
$85.81
$86.96
1-Wochen-Bereich:
$85.81
$88.84
52-Wochen-Spanne:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.11 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.83 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.84 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.75 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Laboratories stock (US0028241000): investors weigh diagnostics strength and medical-device he - AD HOC NEWS
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 - PR Newswire
Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business - Yahoo Finance
Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market - The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside - DirectorsTalk Interviews
Reassessing Abbott Laboratories (ABT) After A 32% One Year Share Price Decline - Yahoo Finance
Abbott Deepens Digital Health Push With New Cardiovascular Diagnostics And Wearables - simplywall.st
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity - Barchart.com
Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - AOL.com
Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum - Insider Monkey
Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT) - Insider Monkey
Three Recession-Resistant Stocks Worth Investors’ Attention - NAI500
Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story - Yahoo Finance
Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026News and Statistics - IndexBox
ABT Stock Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Long term debt to total equity ratio of Abbott Laboratories – BVL:ABTUS - TradingView
Abbott Laboratories Balance Sheet – BVL:ABTUS - TradingView
NEC Baby Formula Lawsuit & Settlement | May 2026 Update - Lawsuit Information Center
Buying pulsed field ablation systems: What hospitals should know - Modern Healthcare
3 Stocks to Buy if You Think the Economy Is Heading for a Recession - The Motley Fool
Abbott Laboratories stock (US0028241000): diabetes business and latest earnings in focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): investors eye upcoming Q4 2025 earnings call and biosimila - AD HOC NEWS
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum - Yahoo Finance
Abbott Laboratories stock (US0028241000): steady medical devices player after latest quarterly updat - AD HOC NEWS
Worker says Abbott fired him over a chat his coworker started - hcamag.com
ECMC debuts new high-tech blood & urine lab to cut down on processing times by 20 percent - WKBW
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Spinal Cord Stimulator Problems Resulted in Severe Paralysis: Lawsuit - AboutLawsuits.com
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109 - 富途牛牛
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings - Yahoo Finance
Abbott Laboratories stock (US0028241000): steady momentum after latest earnings and diabetes tech pu - AD HOC NEWS
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity? - simplywall.st
Build-A-Bear Workshop and Abbott Laboratories o... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
A Look at Abbott Laboratories (ABT) After 4.1% Gain -- GF Value $127.69 vs Price $87.91 - GuruFocus
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Boston Scientific Bets on Growth Through Strategic M&A Deals - TradingView
Raised full-year 2026 outlook lifts Abbott stock 3.18% - Traders Union
Abbott Laboratories (ABT) is attracting investor attention: Here is what you should know - MSN
Trump’s stock trading spree included North Chicago’s Abbott Labs - Crain's Chicago Business
Abbott stock posts modest gain amid fragile momentum below MA-20 resistance: weekly review - Traders Union
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
ABT Stock Price and Chart — NYSE:ABT - TradingView
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now? - TradingView
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Thrivent Financial for Lutherans Acquires 48,286 Shares of Abbott Laboratories $ABT - MarketBeat
North Dakota State Investment Board Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):